In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because

STUDY MATERIALS
COURSES
MORE
SUCCESS STORY
ADMISSION
STORE

Back

JEE ADVANCE

CLASS XI - XII
CRASH COURSE

CLASS XI - XII

CRASH COURSE

JEE MAIN

CLASS XI - XII
CRASH COURSE

CLASS XI - XII

CRASH COURSE

NEET

CLASS XI - XII
CRASH COURSE

CLASS XI - XII

CRASH COURSE

BITSAT

CLASS XI - XII

CLASS XI - XII

CBSE BOARD

CLASS IX

CLASS X

CLASS XI

CLASS XII

CLASS VI

CLASS VII

CLASS VIII

UP BOARD

CLASS IX
CLASS X
CLASS XI
CLASS XII

CLASS IX

CLASS X

CLASS XI

CLASS XII

CUET

CRASH COURSE

CRASH COURSE

Courses

CLASSROOM COURSES
ONLINE COURSES

ONLINE COURSES

Q.
In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because [2022]

1 retroviral vector is introduced into these lymphocytes.

2 gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages.

3 lymphocytes from patient’s blood are grown in culture, outside the body.

4 genetically engineered lymphocytes are not immortal cells.

Ans.
(4)

In gene therapy for ADA deficiency, lymphocytes from patient’s blood are grown in culture outside the body. A functional ADA cDNA is then introduced into these lymphocytes, which are subsequently returned to patient. As these cells are not immortal, thus patient requires periodic infusion of genetically engineered lymphocytes.

Solution

Q.
In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because [2022]

1 retroviral vector is introduced into these lymphocytes.

2 gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages.

3 lymphocytes from patient’s blood are grown in culture, outside the body.

4 genetically engineered lymphocytes are not immortal cells.

Want Us to Email you About Special Offers & Updates?

Solution

Q. In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because [2022]

1 retroviral vector is introduced into these lymphocytes.

2 gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages.

3 lymphocytes from patient’s blood are grown in culture, outside the body.

4 genetically engineered lymphocytes are not immortal cells.

Want Us to Email you About Special Offers & Updates?

Q.
In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because [2022]